89bio Clinical Study Site

San Antonio, Texas 78229-5069

2 studies enrolling now · 5 studies all time

What they study most

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, NASH, NASH - Nonalcoholic Steatohepatitis, Severe Hypertriglyceridemia

Studies at this site

• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — Recruiting now
• To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia — Completed
• Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) — Completed
• A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH — Completed